2 results
Approved WMOPending
The objectives of this multicenter performance evaluation study comprise an assessment of the analytical performance, the reliability and robustness of the system to obtain a CE mark.
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.